Sparrow Pharmaceuticals Announces Acceptance of Late-Breaking Presentation of Interim Part 1 Results from CAPTAIN-T2D at the Endocrine Society (ENDO) 2026 Annual Meeting

Sparrow will also present Phase 2 data on cardiometabolic improvements in patients with type 2 diabetes

Boston, Massachusetts, June 3, 2026 — Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the presentation of new data at a late-breaking poster presentation of interim Part 1 results from CAPTAIN-T2D at the Endocrine Society (ENDO) Annual Meeting taking place from June 13-16, 2026, in Chicago, IL.

The CAPTAIN-T2D trial (NCT07296484) is a Phase 2b study evaluating clofutriben’s ability to improve glycemic control and metabolic health in patients who have difficult-to-control Type 2 diabetes (T2D) with elevated cortisol (EC). Part 1 of the trial is evaluating patients with T2D and EC risk factors for trial eligibility and the presence of EC.

Conference details are as follows:

ENDO 2026 – Endocrine Society Annual Meeting (June 13-16)

Title: Prevalence of Elevated Cortisol in Difficult-to-Control Type 2 Diabetes: Interim Results for CAPTAIN-T2D, a Phase 2 Trial of Clofutriben

Format: Late-breaking Poster Presentation

Date and Time: Saturday, June 13, 2026 9:30 AM - 4:30PM CT

Poster #: SAT-634

Presenter: Elena Christofides, MD, Endocrinology Associates, Columbus, OH, United States

Title: Analysis of Cardiometabolic Effects From a Randomized, Placebo-Controlled, Clinical trial of Clofutriben in Adults with Type 2 Diabetes (T2D)

Format: Abstract Poster Presentation

Date and Time: Saturday, June 13, 2026 9:30 AM - 4:30 PM CT

Poster #: SAT-625

Presenter: Frank Czerwiec, MD, Chief Medical Officer, Sparrow Pharmaceuticals Inc., Miami, Florida, United States